Show simple item record

dc.contributor.authorMatsuo, Yasuhiro
dc.contributor.authorKamitani, Tetsu
dc.date.accessioned2010-09-24T21:05:58Z
dc.date.available2010-09-24T21:05:58Z
dc.date.issued2010-05-13en_US
dc.identifier.citationPLoS One. 2010 May 5; 5(5):e10481en_US
dc.identifier.issn1932-6203en_US
dc.identifier.pmid20463956en_US
dc.identifier.doi10.1371/journal.pone.0010481en_US
dc.identifier.urihttp://hdl.handle.net/10675.2/28
dc.description.abstractBACKGROUND: Melanoma is the major cause of skin cancer death worldwide. Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes. Importantly, epidemiological studies have reported co-occurrence of melanoma and Parkinson's disease, suggesting that these two diseases could share common genetic components. METHODOLOGY/PRINCIPAL FINDINGS: Recently, we found that human melanoma cell lines highly express alpha-synuclein, whereas the protein is undetectable in the non-melanoma cancer cell lines tested. To investigate the expression of alpha-synuclein in human melanoma tissues, we immunostained sections of melanoma, nevus, non-melanocytic cutaneous carcinoma, and normal skin. alpha-Synuclein was positively detected in 86% of the primary and 85% of the metastatic melanoma sections, as well as in 89% of nevus sections. However, alpha-synuclein was undetectable in non-melanocytic cutaneous carcinoma and normal skin. CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi. Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
dc.rightsThe PMC Open Access Subset is a relatively small part of the total collection of articles in PMC. Articles in the PMC Open Access Subset are still protected by copyright, but are made available under a Creative Commons or similar license that generally allows more liberal redistribution and reuse than a traditional copyrighted work. Please refer to the license statement in each article for specific terms of use. The license terms are not identical for all articles in this subset.en_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntigens, Neoplasm / metabolismen_US
dc.subject.meshBrain Neoplasms / metabolism / pathologyen_US
dc.subject.meshCell Line, Tumoren_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMelanins / metabolismen_US
dc.subject.meshMelanoma / metabolism / pathologyen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Proteins / metabolismen_US
dc.subject.meshNevus / metabolism / pathologyen_US
dc.subject.meshParkinson Disease / metabolism / pathologyen_US
dc.subject.meshPigmentationen_US
dc.subject.meshRetinoblastoma / metabolism / pathologyen_US
dc.subject.meshSkin Neoplasms / metabolism / pathologyen_US
dc.subject.meshTumor Markers, Biological / metabolismen_US
dc.subject.meshalpha-Synuclein / metabolismen_US
dc.titleParkinson's disease-related protein, alpha-synuclein, in malignant melanoma.en_US
dc.typeJournal Articleen_US
dc.typeResearch Support, N.I.H., Extramuralen_US
dc.typeResearch Support, Non-U.S. Gov'ten_US
dc.identifier.pmcidPMC2864738en_US
dc.contributor.corporatenameCenter for Molecular Chaperone/Radiobiology & Cancer Virologyen_US
refterms.dateFOA2019-04-09T16:49:10Z
html.description.abstractBACKGROUND: Melanoma is the major cause of skin cancer death worldwide. Parkinson's disease is a neurodegenerative disorder that is caused by mutation of alpha-synuclein or other genes. Importantly, epidemiological studies have reported co-occurrence of melanoma and Parkinson's disease, suggesting that these two diseases could share common genetic components. METHODOLOGY/PRINCIPAL FINDINGS: Recently, we found that human melanoma cell lines highly express alpha-synuclein, whereas the protein is undetectable in the non-melanoma cancer cell lines tested. To investigate the expression of alpha-synuclein in human melanoma tissues, we immunostained sections of melanoma, nevus, non-melanocytic cutaneous carcinoma, and normal skin. alpha-Synuclein was positively detected in 86% of the primary and 85% of the metastatic melanoma sections, as well as in 89% of nevus sections. However, alpha-synuclein was undetectable in non-melanocytic cutaneous carcinoma and normal skin. CONCLUSIONS/SIGNIFICANCE: The Parkinson's disease-related protein, alpha-synuclein, is expressed in both malignant and benign melanocytic lesions, such as melanomas and nevi. Although alpha-synuclein cannot be used to distinguish between malignant and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.


Files in this item

Thumbnail
Name:
pone.0010481.pdf
Size:
1.605Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record